PE0116&PE0105 Clinical Trials

1 actively recruiting trial

Also known as: Recombinant Anti-4-1BB Human Monoclonal Antibody Injection, Recombinant Anti-PD1 Human Monoclonal Antibody Injection

Pipeline

Phase 1/2: 1

Top Sponsors

Shanghai HyaMab Biotech Co.,Ltd.1

Indications

Locally Advanced/Metastatic Solid Tumors1
Cancer1

Other1 trial

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.